Both private and public biotech firms stand to benefit.
Leader Ventures launched a fund to provide $300 million in debt and equity to private and public companies. Leader primarily invests in venture-backed companies, including those in the life sciences sectors.

“We are delighted to be investors in Leader’s new fund,” says Richard Harris, manager of M.A.R.S. Lattner, LP, an Atlanta-based family office. “With a solid track record and over 37 years of investing and lending experience, the Leader team has proven their ability to meet the needs of growing companies and deliver top-quartile returns to investors.”

Previous articleAbD Serotec to Manufacture Antibodies against Bacterial-Derived Toxins for U.S. Army
Next articleCallisto Pharmaceuticals Granted Orphan Drug Designation for its Candidate against Carcinoid Tumors